GlaxoSmithKline Stock News

The healthcare team at Citi has turned positive on GSK PLC (LSE:GSK, NYSE:GSK) for the first time in seven years. Pushing the investment bank's analysts over the precipice to 'buy' was the outlook for

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

GSK has been granted US Fast Track designation for bepirovirsen, an investigational treatment for chronic hepatitis B (CHB).  A request was made to US regulator the FDA by the UK pharma due to an un

GSK PLC (LSE:GSK, NYSE:GSK) has reached a confidential settlement regarding a lawsuit in California, which accused its discontinued heartburn medication, Zantac, of causing cancer, thus avoiding a tri

GSK said on Thursday it agreed to confidentially settle one more lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end c

GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.

The RSV shot, called Abrysvo, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.

GSK (GSK) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.64 per share a year ago.

GSK on Wednesday lifted its long-term outlook for 2026-2031 as it predicted new drug and vaccine launches will see its annual sales hit £38 billion by the start of the next decade following the block

GSK PLC (LSE:GSK, NYSE:GSK) on Wednesday increased its outlook for sales out to 2031 driven by a raft of major product launches from 2025. Chief Executive Emma Walmsley said: “We are now planning fo

GSK beat market estimates for fourth-quarter profit and sales on Wednesday, underpinned by a strong launch of its respiratory syncytial virus (RSV) vaccine Arexvy and steady demand for its shingles sh

The U.K.-based company is looking to recover after a lackluster 2023.

One of the most important sectors not only in the financial markets but also in everyone's life, is the healthcare sector. It can provide investors with good returns due to its constant growth and con

GSK is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.